ACP-105
Based on 6 publication(s) in Google Scholar
ACP-105 is an orally available, selective amd potent androgen receptor modulator (SARM), with pEC50s of 9.0 and 9.3 for AR wild type and T877A mutant, respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.92%
- CAS No.: 899821-23-9
- Formule: C16H19ClN2O
- Masse moléculaire:290.79
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Orally Active Compound Library
HY-L061
-
Transcription Factor-Targeted Library
HY-L090
-
Nuclear Receptor Compound Library
HY-L126
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) ACP-105
More- Metabolites. 2021 Feb 1;11(2):85. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Dec 1:1231:123927. [Abstract]
- Drug Test Anal. 2022 Feb;14(2):349-370. [Abstract]
- Drug Test Anal. 2021 May;13(5):916-928. [Abstract]
- Drug Test Anal. 2021 Feb;13(2):283-298. [Abstract]
- Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2026 Feb 26:1-17. [Abstract]
Activité biologique
pEC50: 9.0 (AR wild type), 9.3 (AR T877A mutant)[1].
ACP-105 is an orally available, selective amd potent androgen receptor modulator (SARM), with pEC50s of 9.0 and 9.3 for AR wild type and T877A mutant, respectively. The half-lives of ACP-105 (compound 1) in human hepatocytes is measured and found to be 5.0 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 899821-23-9
-
Appearance Solid
-
Masse moléculaire 290.79
-
Formule C16H19ClN2O
-
Color Light yellow to yellow
-
SMILES
N#CC1=CC=C(N2[C@@H]3C[C@](O)(C)C[C@H]2CC3)C(C)=C1Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Metabolites
Investigation of Equine In Vivo and In Vitro Derived Metabolites of the Selective Androgen Receptor Modulator (SARM) ACP-105 for Improved Doping Control. [Abstract]2021 Feb 1;11(2):85. PMID: 33535528 -
J Chromatogr B Analyt Technol Biomed Life Sci
A multivariate data analysis approach for the investigation of in vitro derived metabolites of ACP-105 in comparison with human in vivo metabolites. [Abstract]2023 Dec 1:1231:123927. PMID: 37972465 -
Drug Test Anal
Identification of equine in vitro metabolites of seven non-steroidal selective androgen receptor modulators for doping control purposes. [Abstract]2022 Feb;14(2):349-370. PMID: 34714606 -
Drug Test Anal
An in vitro assay approach to investigate the potential impact of different doping agents on the steroid profile. [Abstract]2021 May;13(5):916-928. PMID: 33283964 -
Drug Test Anal
High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]2021 Feb;13(2):283-298. PMID: 32852861 -
Food Addit Contam Part A Chem Anal Control Expo Risk Assess
Comprehensive IM-MS approach for SARMs detection in urine: building CCS databases to support food safety monitoring. [Abstract]2026 Feb 26:1-17. PMID: 41747154
Solvant et solubilité
DMSO : ≥ 103 mg/mL (354.21 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
Mice[2]
Two-month-old C56Bl/6J female mice are kept on a 12:12 hr light-dark schedule (lights on at 6 AM) with lab chow and water given ad libitum. Following i.p. anesthesia (ketamine, 80 mg/kg and xylazine, 20 mg/kg), mice are sham-irradiated (n=7 sham vehicle-treated mice and n=7 ACP-105-treated mice) or irradiated (n=8 vehicle-treated mice and n=7 ACP-105-treated mice) using a dose of 10 Gy in a Mark 1 Cesium Irradiator. Twenty-four hours following irradiation, the mice are implanted with Alzet minipumps filled with ACP-105 at 1 mg/kg/day or 1.09 mg/200 μL in 10% Tween in saline or vehicle. Behavioral testing starts two weeks after irradiation. Mice receives three trials per day for three subsequent days. Mice are tested for fear conditioning in week 2. During contextual fear conditioning, mice learn to associate the environmental context with a mild foot shock. Contextual conditioned fear is assessed during the first 3 minutes of the contextual test trial when freezing behavior is most robust. Cued conditioned fear is assessed during the presentation of the tone (the last 3 minutes of the trial)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Schlienger N, et al. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators. J Med Chem. 2009 Nov 26;52(22):7186-91. [Content Brief]
[2]. Dayger C, et al. Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in sham-irradiated and irradiated female mice. Brain Res. 2011 Mar 24;1381:134-40. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4389 mL | 17.1945 mL | 34.3891 mL | 85.9727 mL |
| 5 mM | 0.6878 mL | 3.4389 mL | 6.8778 mL | 17.1945 mL | |
| 10 mM | 0.3439 mL | 1.7195 mL | 3.4389 mL | 8.5973 mL | |
| 15 mM | 0.2293 mL | 1.1463 mL | 2.2926 mL | 5.7315 mL | |
| 20 mM | 0.1719 mL | 0.8597 mL | 1.7195 mL | 4.2986 mL | |
| 25 mM | 0.1376 mL | 0.6878 mL | 1.3756 mL | 3.4389 mL | |
| 30 mM | 0.1146 mL | 0.5732 mL | 1.1463 mL | 2.8658 mL | |
| 40 mM | 0.0860 mL | 0.4299 mL | 0.8597 mL | 2.1493 mL | |
| 50 mM | 0.0688 mL | 0.3439 mL | 0.6878 mL | 1.7195 mL | |
| 60 mM | 0.0573 mL | 0.2866 mL | 0.5732 mL | 1.4329 mL | |
| 80 mM | 0.0430 mL | 0.2149 mL | 0.4299 mL | 1.0747 mL | |
| 100 mM | 0.0344 mL | 0.1719 mL | 0.3439 mL | 0.8597 mL |
ACP-105 Related Classifications
HY-112256 Related Classifications
Powered by Bioz